Accelerating Drug Discovery for FTD RFP
Funds lead optimization and in vivo testing for frontotemporal dementia candidates, including medicinal chemistry and preclinical studies.
Eligibility · Global — open worldwide
Accelerating Drug Discovery for FTD is a joint RFP from the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), targeting the lead optimization and in vivo testing stages of small molecule and biologic drug development for frontotemporal dementia. FTD — encompassing disorders caused by TDP-43, tau, FUS, and related pathologies — affects approxim…
Lead optimization (medchem refinement + in vitro ADME) and in vivo testing for FTD drug candidates. Small molecules and biologics only; target ID, validation, and screening excluded.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline